Innovating Works

kINPen

Financiado
Developing a high innovative portable cold plasma device for efficient healing o...
Developing a high innovative portable cold plasma device for efficient healing of chronic wounds in veterinary medicine The veterinary sector urgently needs to revolutionize their treatment methods in order to solve the present antibiotic overconsumption and related growing resistance. This constitutes an important market opportunity for new techno... The veterinary sector urgently needs to revolutionize their treatment methods in order to solve the present antibiotic overconsumption and related growing resistance. This constitutes an important market opportunity for new technologies. Current non-pharmacological infection treatments such as ultrasound, electrical stimulation, laser or LED, are less efficient, given their cost, unpleasant feeling, treatment-time or required area. Therefore, neoplas GmbH successfully developed kINPen®VET, a non-pharmacological, high-innovative and portable cold plasma device for efficient healing of chronic wounds in farm and pet animals. It stimulates and accelerates physiological wound healing and is highly effective against typical wound bacteria, multidrug-resistant microorganisms and fungi, obtaining antiviral, antimicrobial, antifungal and anti-inflammatory effects on the treated surface without the need of antibiotics or developing microorganism resistance. It is based on cold plasma and uses the advantages of the Plasma Effect (ionized gas, electrons and ions, as well as radicals, excited species, UV radiation and electromagnetic fields). KINPen®VET will provide a 100% safe and manoeuvrable device, leading to a more cost-effective and sustainable veterinary medical treatment. kINPen®VET’s commercialization will generate high revenues in the targeted market segments of animal health and wellbeing and organic animal farming (market share 50%). This equals to an approximate number of more than 110.000 systems presenting a turnover of €950 million only in Europe. This ambitious target is reachable by forming a European network of regional suppliers, representatives and costumers in each targeted country. The production costs have been calculated with 5.900 €/ unit in the first 3 years and with a rising production the costs will be reduced to ca. 4.600 €/unit. The sales price is targeted with 8.900 €/unit and will allow a calculated return on investment in under 18 months. ver más
30/04/2019
NEOPLAS
71K€
Duración del proyecto: 4 meses Fecha Inicio: 2018-12-04
Fecha Fin: 2019-04-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-04-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020: SME instrument
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 71K€
Líder del proyecto
NEOPLAS GMBH No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5